65,437 trials
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Primary: Number of Participants With Overall Response — 2; 1; 0; 1 Participants
Arthritis, Rheumatoid
Primary: Disease Activity Score 28 (DAS28) in Participants With Positive Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (ACCP) at Last Follow-up Visit (Month 12)…
Primary Alcohol Use Disorder
Primary: Relapse Rates — 13; 15; 14; 18 Participants
Bronchoscopy
Primary: Hypoxemia During Maintenance — 8; 14 Participants
HTLV I Associated Myelopathy
Primary: Number of Patient With Lack of Objective Clinical Improvement — 0 Participants
Multiple Myeloma
Primary: Percentage of Participants With 1-year Response Rate of CR/sCR — 52.9; 50.0 percentage of participants — p=0.3657
Dementia · Alzheimer Disease · Dementia, Vascular
Primary: Quality of Life-Alzheimer's Disease, Change From Baseline to 1 Year — -1.43; -1.12 units on a scale — p=0.04
Smoking Cessation · Smoking, Tobacco
Primary: Ease-of-use and Helpfulness of the App — 2.39; 2.36; 2.42; 2.39 units on a scale
Internet Gaming Disorder
Primary: Percentage of Participants Who Completed All 6 Sessions — 40.6 percentage of participants
Migraine in Adolescents
Primary: Number of Migraine/Migrainous Days Per 28 Day Period — 3.6; 4.9 days
Prostate Cancer
Primary: Best Objective Response Rate (ORR) — 29.8 Percentage of participants
Pancreatic Cancer
Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants
ST Elevation Myocardial Infarction · NSTEMI - Non-ST Segment Elevation MI
Primary: Evaluation of Platelet Inhibition — 94; 141 P2Y12 Reaction Units (PRU)
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Candida Vulvovaginitis
Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 119; 37; 69; 47 Participants